Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing
• Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY DRUG CLASS
• Segmentation by drug class
• Comparison by drug class
• Somatostatin analogs – Market size and forecast 2017-2022
• GH receptor antagonists – Market size and forecast 2017-2022
• Dopamine agonists – Market size and forecast 2017-2022
• Recombinant human IGF-1 – Market size and forecast 2017-2022
• Market opportunity by product

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 14: MARKET TRENDS
• Growing popularity of drugs over surgeries
• Focus on long-acting novel formulations

PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Ipsen
• Novartis
• Pfizer

PART 17: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Parent market
Exhibit 02: Global acromegaly and gigantism drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global acromegaly and gigantism drugs market 2017-2022 ($ mn)
Exhibit 09: Global acromegaly and gigantism drugs market: Year-over-year (YoY) growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials for global acromegaly and gigantism drugs market
Exhibit 20: Segmentation of global acromegaly and gigantism drugs market by drug class 2017-2022 (%)
Exhibit 21: Comparison by drug class
Exhibit 22: Somatostatin analogs – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Somatostatin analogs – YoY growth 2018-2022 (%)
Exhibit 24: GH receptor antagonists – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: GH receptor antagonists – YoY growth 2018-2022 (%)
Exhibit 26: Dopamine agonists – Market size and forecast 2017-2022 ($ mn)
Exhibit 27: Dopamine agonists – YoY growth 2018-2022 (%)
Exhibit 28: Recombinant human IGF-1 – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Recombinant human IGF-1 – YoY growth 2018-2022 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Segmentation of global acromegaly and gigantism drugs market by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Americas – YoY growth 2018-2022 (%)
Exhibit 36: Top three countries in Americas
Exhibit 37: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 38: EMEA – YoY growth 2018-2022 (%)
Exhibit 39: Top three countries in EMEA
Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC – YoY growth 2018-2022 (%)
Exhibit 42: Top three countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Percentage increase in GDI of India, China, and US for 2011-2016
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Ipsen – Vendor overview
Exhibit 51: Ipsen – Business segments
Exhibit 52: Ipsen – Organizational developments
Exhibit 53: Ipsen – Geographic focus
Exhibit 54: Ipsen – Segment focus
Exhibit 55: Ipsen – Key offerings
Exhibit 56: Ipsen– Key customers
Exhibit 57: Novartis – Vendor overview
Exhibit 58: Novartis – Business segments
Exhibit 59: Novartis – Organizational developments
Exhibit 60: Novartis – Geographic focus
Exhibit 61: Novartis – Segment focus
Exhibit 62: Novartis – Key offerings
Exhibit 63: Pfizer – Vendor overview
Exhibit 64: Pfizer – Business segments
Exhibit 65: Pfizer – Organizational developments
Exhibit 66: Pfizer – Geographic focus
Exhibit 67: Pfizer – Segment focus
Exhibit 68: Pfizer – Key offerings
Exhibit 69: Pfizer – Key customers